CAR-T Cell Therapies Show Promise for Autoimmune Disease at ACR Convergence 2025 Save
Two pioneering studies presented at ACR Convergence 2025 spotlight the potential of CAR-T cell therapies to transform treatment for systemic lupus erythematosus (SLE) and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and long-term disease remission.
Dual-Targeted CAR-T Therapy for Lupus
Abstract #1532
Researchers unveiled preliminary results from a study of CTA313, a dual-targeted CAR-T therapy designed to attack both CD19 and BCMA. In patients with active SLE, the therapy demonstrated encouraging safety, efficacy, and cellular kinetics. By targeting both B cells and plasma cells, CTA313 may offer a novel therapeutic option for individuals with refractory lupus.
CD19 CAR-T Therapy Across Autoimmune Conditions
Abstract #2452
Another study explored CTA311, a CD19-targeted CAR-T therapy, in patients with active autoimmune diseases. The data revealed promising early outcomes, highlighting CAR-T’s potential to recalibrate immune responses and induce durable remission across a spectrum of autoimmune disorders.
Together, these studies underscore a growing momentum in autoimmune research—one that embraces cellular therapies and precision immunology to improve outcomes for patients facing chronic, complex conditions.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.